Trypanosoma cruzi Sirtuin 2 as a Relevant Druggable Target: New Inhibitors Developed by Computer-Aided Drug Design

克氏锥虫 Sirtuin 2 作为相关可用药靶点:通过计算机辅助药物设计开发的新型抑制剂

阅读:13
作者:Glaucio Monteiro Ferreira, Thales Kronenberger, Vinicius Gonçalves Maltarollo, Antti Poso, Fernando de Moura Gatti, Vitor Medeiros Almeida, Sandro Roberto Marana, Carla Duque Lopes, Daiane Yukie Tezuka, Sérgio de Albuquerque, Flavio da Silva Emery, Gustavo Henrique Goulart Trossini

Abstract

Trypanosoma cruzi, the etiological agent of Chagas disease, relies on finely coordinated epigenetic regulation during the transition between hosts. Herein we targeted the silent information regulator 2 (Sir2) enzyme, a NAD+-dependent class III histone deacetylase, to interfere with the parasites' cell cycle. A combination of molecular modelling with on-target experimental validation was used to discover new inhibitors from commercially available compound libraries. We selected six inhibitors from the virtual screening, which were validated on the recombinant Sir2 enzyme. The most potent inhibitor (CDMS-01, IC50 = 40 μM) was chosen as a potential lead compound.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。